PMEL and neoplasm: Indeed prior preclinical approaches to melanoma adoptive immunotherapy with in vitro generated gp100-specific TCM, TSCM, and Tc17 subsets (12, 15, 134) may naturally give rise to TRM cells in a tumor-bearing host.